PeptidePedia The community reference

Contributions of ComparisonCato

User contributions·22 logged edits·page 1 of 1

Contributions by ComparisonCato, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 499 edits includes activity predating the current log.

  1. 21:12, 19 Jul 2026 (diff | hist) Dose escalation schedule 4,993 ±0 state the syringe graduation the unit figure assumes
  2. 12:05, 16 Jul 2026 (diff | hist) Dulaglutide 5,490 ±0 m fix a dangling clause
  3. 18:04, 19 Feb 2026 (diff | hist) Dulaglutide 5,490 ±0 attribute the potency comparison to the head-to-head trial rather than to two separate ones
  4. 17:28, 8 Jan 2026 (diff | hist) Sigma-Aldrich (Shanghai) Trading 18,421 +1,133 clarify that no manufacturing or marketing authorisation is claimed or established
  5. 18:48, 18 Nov 2025 (diff | hist) Lixisenatide 4,195 ±0 ce per PP:MOS
  6. 14:28, 26 Sep 2025 (diff | hist) Third-party testing 7,489 ±0 rm the ranking language; this wiki publishes no ranking
  7. 08:28, 21 Aug 2025 (diff | hist) Triple agonist 4,269 +282 state plainly that the research-use-only form is not approved for human use
  8. 19:12, 7 Aug 2025 (diff | hist) Dulaglutide 5,490 +360 correct the molar mass — source gives the free-base figure, we had the salt
  9. 12:11, 6 Aug 2025 (diff | hist) Cold chain 24,029 +1,034 expand §Storage classes and their definitions
  10. 16:46, 6 Jul 2025 (diff | hist) GLP-1 receptor agonist 9,922 +164 m copyedit
  11. 22:22, 26 May 2025 (diff | hist) Orforglipron 4,505 ±0 m add the year of first marketing authorisation, with the regulator named
  12. 10:27, 28 Mar 2025 (diff | hist) Lixisenatide 3,215 ±0 expand §Current position
  13. 13:09, 25 Feb 2025 (diff | hist) CagriSema 3,887 +111 de-duplicate a repeated sentence
  14. 15:25, 21 Jan 2025 (diff | hist) Semaglutide 7,098 +365 add the structural figure and caption it properly
  15. 17:06, 7 Dec 2024 (diff | hist) Lixisenatide 2,302 ±0 m add the molecular formula to the infobox
  16. 05:47, 7 Dec 2024 (diff | hist) Retatrutide 4,579 +98 m expand §Reported clinical findings
  17. 23:44, 26 Oct 2024 (diff | hist) Peptide 3,903 +226 rm the shipping recommendation — that is advice, not description
  18. 05:56, 6 Oct 2024 (diff | hist) Haemoglobin A1c 2,574 ±0 m correct the reference interval — the source gives it for fasting samples
  19. 07:25, 5 Oct 2024 (diff | hist) Cagrilintide 2,406 +304 British spelling per PP:MOS
  20. 20:30, 27 Jul 2024 (diff | hist) Glucagon 2,758 ±0 add the discontinued indication with its date
  21. 09:00, 19 Jul 2024 (diff | hist) Timeline of incretin therapeutics 1,103 +1,103 N start article on the compound
  22. 16:04, 7 Jul 2024 (diff | hist) Semaglutide 3,178 +571 close an unbalanced quotation mark